Future Journal of Pharmaceutical Sciences

Table 8 Acid degradation peak results

From: Development and validation of stability indicating UPLC method for the simultaneous estimation of triamterene and hydrochlorothiazide in combined dosage forms using quality by design approach

	Sample	Retention time	Area	Height	USP	USP plate	Purity1 angle	Purity1 threshold
01	Peak1	0.067	284	278	0.91	77.75
02	Triamterene	0.925	822,994	302,607	1.72	2402.80	0.110	0.375
03	Peak1	1.285	17,228	6303	1.66	5408.99	2.203	4.363
04	Peak1	1.548	28,793	7051		4588.52	26.586	4.024
05	HCTZ	1.742	931,060	233,776	1.29	4582.89	0.262	0.348
06	Peak1	2.516	1305	442	0.60	32,440.89
07	Peak1	4.134	152	228	1.60	347,087.42
08	Peak1	5.817	113	225	1.00	649,614.07

Back to article page